CD18 inhibits progression of kidney cancer by down-regulating Treg cell levels.
CONCLUSIONS: CD18-/- down-regulates Treg cells and inhibits the pathogenesis of renal cell carcinoma.
PMID: 31002125 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Genetics | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology